Somogy Varmegyei Kaposi Mor Oktato Korhaz
- Address
- lock Available on a paid plan
Somogy Varmegyei Kaposi Mor Oktato Korhaz - Advanced Clinical Research Center
Somogy Varmegyei Kaposi Mor Oktato Korhaz is a comprehensive clinical research center with extensive experience across multiple therapeutic areas. The institution demonstrates particular strength in oncology research, participating in advanced immunotherapy trials for various cancers, and dermatological conditions, with significant involvement in atopic dermatitis and psoriasis studies. The center's research portfolio reflects expertise in conducting complex Phase 3 trials involving novel biological agents and combination therapies.
- Cardiovascular diseases including atherosclerotic cardiovascular disease, acute coronary syndrome, atrial fibrillation, and thromboembolic disorders with focus on stroke prevention
- Oncology trials spanning triple-negative breast cancer, small cell lung cancer, colorectal cancer, and diffuse large B-cell lymphoma with advanced immunotherapy approaches
- Dermatological conditions including moderate-to-severe atopic dermatitis, plaque psoriasis, and hidradenitis suppurativa
- Gastroenterology and nephrology research including ulcerative colitis, hepatic encephalopathy, IgA nephropathy, and chronic kidney disease-associated conditions
The research center demonstrates capability in managing diverse patient populations, from adolescents to adults, across both common and rare diseases. Their participation in international multicenter trials indicates robust infrastructure for conducting randomized, double-blind, placebo-controlled studies with sophisticated endpoints. The institution's involvement in studies evaluating novel anticoagulants, immunotherapies, and targeted biologics positions them at the forefront of translating innovative therapies into clinical practice, particularly in areas such as endometriosis-related pain and chronic lymphocytic leukemia.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 13 therapeutic areas and 15 of 213 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 212 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 23 by active trials.
- 1Merck Sharp & Dohme LLC4active
lock +22 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC12trials
lock +20 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Somogy Varmegyei Kaposi Mor Oktato Korhaz
lock Showing 1 of 120 trials — the rest is available on a paid plan.
IMP list
lock Showing 1 of 213 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 16 | Unknown | 2018-08-24 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.